3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
5
Recruiting
3
Unknown
2
Terminated
2
Active not recruiting
2
Withdrawn
1
Sponsor Class
OTHER
2
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
Dermatologic
2
Conditions
Carcinoma, Non-Small-Cell Lung
13
Stomach Neoplasms
12
Colorectal Neoplasms
8
Breast Neoplasms
8
Esophageal Neoplasms
7
Rectal Neoplasms
6
Lung Neoplasms
6
Carcinoma, Hepatocellular
6
Glioblastoma
5
Brain Neoplasms
5
Neoplasms
4
Neoplasm Metastasis
4
Colonic Neoplasms
4
Cholangiocarcinoma
4
Uterine Cervical Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
3
Ovarian Neoplasms
3
Lymphatic Metastasis
3
Glioma
3
Endometrial Neoplasms
3
Disease
3
Astrocytoma
3
Thyroid Neoplasms
2
Recurrence
2
Pain, Postoperative
2
Oropharyngeal Neoplasms
2
Melanoma
2
Laryngeal Neoplasms
2
Gliosarcoma
2
Gastrointestinal Stromal Tumors
2
Interventions
Nivolumab
25
pembrolizumab
20
Ipilimumab
15
toripalimab
12
Temozolomide
11
Biopsy
8
Dacarbazine
7
Cyclophosphamide
6
Blood Specimen Collection
6
trametinib
5
fludarabine
5
dabrafenib
5
camrelizumab
5
atezolizumab
5
Gene Expression Profiling
5
Chemotherapy, Adjuvant
5
durvalumab
4
binimetinib
4
aldesleukin
4
Interleukin-2
4
Injections
4
Carboplatin
4
tislelizumab
3
palbociclib
3
encorafenib
3
apatinib
3
Sorafenib
3
Paclitaxel
3
Introns
3
Drug Therapy
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Unknown
×
Melanoma
×
Surgical Procedures, Operative
×
Clear all
NCT02977052
2023-11-15
OpACIN-neo
The Netherlands Cancer Institute
Phase 2
Unknown
186 enrolled
NCT05402059
2022-06-15
ISABELLA
MelanomaPRO, Russia
Unknown
1,570 enrolled